Key Highlights
- General and administrative expenses jumped to USD 37.4 million from USD 9.7 million in the third quarter, as the company built out commercial infrastructure, including USD 15.4 million more in professional fees.
- The third-quarter net loss was USD 57.3 million, or USD 0.64 per share, compared with USD 36.9 million, or USD 0.52 per share, a year earlier.
- Cash, cash equivalents and investments were USD 624.7 million on September 30, 2026, and the FDA target action date for lorundrostat is December 22, 2026.
- Nine-month net loss reached USD 337.7 million, versus USD 122.4 million, driven by a USD 200.0 million upfront payment to Tanabe Pharma in June 2026.
Pre-Launch Hiring and Fees Nearly Quadruple G&A
Mineralys Therapeutics (NASDAQ:MLYS) filed its 10-Q for the quarter ended September 30, 2026 on November 4, 2026. General and administrative expense rose USD 27.7 million to USD 37.4 million, which the company ties to preparing for commercialization: USD 15.4 million of higher professional fees and USD 11.4 million of added personnel costs. Research and Development expense fell USD 8.8 million to USD 22.7 million as the pivotal lorundrostat program concluded in 2025. The company has no product revenue. The net loss widened by USD 20.4 million to USD 57.3 million, even though other income, net fell to USD 2.8 million.
Lorundrostat Awaits an FDA Decision on December 22
The company develops lorundrostat, an oral aldosterone synthase inhibitor for uncontrolled or resistant hypertension. It submitted its new drug application in December 2025, the FDA accepted it, and the target action date is December 22, 2026. The filing says an advisory committee meeting is not currently anticipated. In March 2026 a Phase 2 trial in sleep apnea did not show a clinically meaningful difference from placebo on its primary endpoint, though blood pressure fell 11.1 mmHg on treatment against 1.0 mmHg on placebo. Management believes cash is sufficient to fund planned operations, including launch, for at least twelve months.
Tanabe Buyout, Term Loan and Dilution Risks
On June 2, 2026 the company paid Tanabe USD 200.0 million to end Royalty obligations on lorundrostat, while still owing up to USD 255.0 million of commercial milestones. It also drew USD 100.0 million of a senior secured loan of up to USD 500.0 million, with the USD 150.0 million Tranche B tied to FDA approval. A June stock offering raised about USD 143.6 million net and at-the-market sales added USD 20.2 million for the nine months. Risks include an unfavorable FDA decision, repayment acceleration if approval is not achieved by September 30, 2027, and further share issuance. Weighted shares rose to 89.0 million from 70.6 million.
Where Things Stand
Spending on launch readiness explains it. Mineralys Therapeutics (NASDAQ:MLYS) raised G&A to USD 37.4 million as it hired staff and paid advisers ahead of a possible approval, pushing the quarterly loss to USD 57.3 million. The Balance Sheet holds USD 624.7 million, but the Tanabe payment, the term loan and the Equity raised this year show how much Capital the launch is absorbing. The filing gives no market reaction. The key marker is the FDA action date of December 22, 2026, after which the Tranche B loan draw, launch timing and any further financing needs will become clearer.




_11_13_2026_20_27_09_053340.jpg)

Please wait processing your request...